Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital
Boston
Joined February 2009
- Tweets825
- Following257
- Followers4.7K
- Likes411
It's summer, so let's try another round of Where In The World Is @ASLMENews? As with last year, winner gets a year's membership, including a subscription to the world-famous journal, @JLME_ASLME (If you need a hint, the second photo provides some context for the first one)
Congrats to contest winner @DrMarkLythgoe for a remarkably precisely accurate submission! Mark, I will email to process your prize. Thanks to everyone else for playing -- maybe next time!
Happy to have the opportunity to hype this huge new piece that happened to hit on this holiday: led by @bnrome, a viewpoint on issues relating to the emergence (hooray!) of new biosimilar Humira: pubmed.ncbi.nlm.nih.gov/3702…
Aaron Kesselheim retweeted
Introduction of a citrate-free version of adalimumab in 2018 avoided Medicaid's inflationary rebates and led to >$4B excess spending from 2018-2021. ja.ma/3SP2qlf @charliecwlee @akesselheim @bnrome @PORTAL_Research
Aaron Kesselheim retweeted
New cross-sectional study finds that more than half of #AcceleratedApproval confirmatory trials are completed after the deadline set by the FDA. @akesselheim @bnrome @PORTAL_Research ja.ma/3KndEuB
Important session next week on racial discrimination and pulse oximetry in the @PORTAL_Research and Center for Bioethics health policy and bioethics consortium! Register please!
This Post is from an account that no longer exists. Learn more
Aaron Kesselheim retweeted
Despite new penalties via the #InflationReductionAct, drug companies raised prices for nearly 1k drugs in January. Is Congress' attempt to curb drug price hikes failing?
Read the #OpEd by Alexander C. Egilman, @akesselheim & @bnrome of @PORTAL_Research.
bit.ly/3lVo9vA
Aaron Kesselheim retweeted
Thanks for a great presentation @sariahmed!
Presented my mifepristone work to @PORTAL_Research, thanks for the great feedback! And thanks @LarochelleMarc for joining and @pauljchristine for holding my hand w all the epi and stats.
Aaron Kesselheim retweeted
Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, according this cross-sectional study. @LSEHealthPolicy @PortalResearch @akesselheim @robinjforrest_ ja.ma/3lK4vCD
Aaron Kesselheim retweeted
Is It Business as Usual for the Drug Industry?
In @medpagetoday, Alex Egilman, @akesselheim, and I explain why drug companies continued to raise prices in 2023 despite the #InflationReductionAct
medpagetoday.com/opinion/sec…
Watch @PORTAL_Research @AmeetSarpatwari speak at today's @SenateHELP hearing on COVID vaccine pricing -- and check out our @BostonGlobe op-ed from @DrHussainL on the public funding critical to its development: bostonglobe.com/2023/03/21/o…
New entry in the @NEJM Fundamentals of Health Law Series! Consolidation and competition in the health care sector -- and implications for patients and pricing; from Jaime King. Collect them all!: nejm.org/doi/full/10.1056/NE…
Next in our @NEJM Fundamentals of Health Law series: a focus on fraud/abuse and COI rules with Prof Zack Buck from Univ of Tennessee: nejm.org/doi/pdf/10.1056/NEJ…
Aaron Kesselheim retweeted
Policy makers have several options to maximize benefits from public investments and improve returns for the entire global community, write @DrHussainL, Sarosh Nagar, Jerry Avorn, and @akesselheim.
trib.al/TmiXjUb
Aaron Kesselheim retweeted
The FDA has long conducted its oversight of prescription drugs and other products with deference from courts. But mounting judicial skepticism of agency authority threatens to upend this norm. nej.md/3J8jKx0
ALT "When the FDA acts to regulate medical products, it can no longer assume that a reasonable interpretation of the law will be upheld in court." Perspective C. Joseph Ross Daval, J.D., Liam Bendicksen, B.A., and Aaron S. Kesselheim, M.D., J.D., M.P.H.
Aaron Kesselheim retweeted
Great article from @ZacharyBrennan
@endpts today covering our new work @Health_Affairs on inhaler patents and litigation.
Where are all the generic inhalers for asthma and COPD? Researchers call for patent and FDA reforms - endpts.com/where-are-all-the…
Aaron Kesselheim retweeted
According to new findings, some of the most heavily advertised drugs are often no better at treating a disease than lesser known options hrvd.me/DrugAdvertising986t
Aaron Kesselheim retweeted
Interesting point by @sean_r_dickson… maybe the new Medicaid rebate rules were one of the factors driving Lilly to lower list prices.
@akesselheim and I wrote about this in @JAMAInternalMed back in 2021: jamanetwork.com/journals/jam…
Next in our @NEJM Fundamentals of Health Law series: a focus on fraud/abuse and COI rules with Prof Zack Buck from Univ of Tennessee: nejm.org/doi/pdf/10.1056/NEJ…
Our @NEJM Fundamentals of Health Law series continues with an overview of regulation and reproductive medicine from @ProfessorMutch: nejm.org/doi/full/10.1056/NE…
Aaron Kesselheim retweeted
Medicare price negotiation under the #InflationReductionAct could reduce prescription drug spending by at least 5% in the first 3 years, according to a simulation study. @bnrome @PORTAL_Research ja.ma/3XmOkrJ
Yesterday, filed an amicus brief in the Amgen v Sanofi @USSupremeCourt case detailing why undeserved broad drug patents harm patients and innovation, w/ Jerry Avorn, @NC4HR, Arnold Ventures, & others. Thanks to the great team at Fish & Richardson: supremecourt.gov/DocketPDF/2…